Swedish Orphan Biovitrum AB (SOBI) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Swedish Orphan Biovitrum AB (Sobi), formerly Biovitrum AB, is an integrated biopharmaceutical company that focuses on the development of products for the treatment of rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on haemophilia, inflammation and genetic and metabolic diseases. The companys products include Alprolix, Ammonaps, Elocta, Kepivance, Kineret and Orfadin. Sobi also manufactures and markets specialty and rare disease products for partner companies. It has operational presence in Europe, the Middle East and North Africa. Sobi is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB (SOBI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deal Details 14
Private Equity 14
Swedish Orphan Biovitrum Plans to Sell Partner Products Business 14
Partnerships 15
Baylor Research Enters into Licensing Agreement with Swedish Orphan Biovitrum 15
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 16
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 17
ModiQuest Research Enters into Agreement with Swedish Orphan Biovitrum 18
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 19
Biogens Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 20
Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 21
Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 22
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 23
Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 24
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 25
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 27
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 29
Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 30
Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 31
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 32
Licensing Agreements 33
Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 33
Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 34
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Only for Children Pharma For Neonatology Treatment 35
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 36
Debt Offering 38
Swedish Orphan Biovitrum Announces Private Placement Of Senior Bonds Due 2017 For US$86 Million 38
Swedish Orphan Biovitrum AB - Key Competitors 39
Swedish Orphan Biovitrum AB - Key Employees 40
Swedish Orphan Biovitrum AB - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 43
Financial Announcements 43
Apr 26, 2018: Sobi publishes the report for the first quarter 2018 43
Feb 22, 2018: Sobi publishes its report for the fourth quarter and full-year 2017 44
Oct 25, 2017: Sobi publishes its report for the third quarter 2017 45
Jul 19, 2017: Sobi publishes its report for the second quarter 2017 46
Apr 28, 2017: Sobi publishes its report for the first quarter 2017 47
Feb 16, 2017: Sobi publishes its report for the fourth quarter and full year 2016 48
Corporate Communications 49
Feb 26, 2018: Swedish Orphan Biovitrum Appoints Henrik Stenqvist As New Chief Financial Officer 49
Oct 06, 2017: Norbert Oppitz joins Sobi as new Senior Vice President, Specialty Care 50
Jun 07, 2017: Chief Operating Officer Alan Raffensperger to leave Sobi 51
May 04, 2017: Guido Oelkers Appointed President and CEO at Sobi 52
Apr 07, 2017: Theresa Heggie resigns from the Board of Directors and will not be proposed for re-election at Sobis annual general meeting 2017 53
Jan 09, 2017: CEO Geoffrey McDonough to leave Swedish Orphan Biovitrum 54
Product News 55
12/13/2017: Sobi Launches Orfadin (nitisinone) Ambassador Program to Support Patients and Caregivers Living with Hereditary Tyrosinemia Type 1 (HT-1) 55
11/27/2017: Sobi Receives Approval From Health Canada for Orfadin (nitisinone) Oral Suspension for the Treatment of HT-1 56
09/05/2017: Sobi Receives Approval From the FDA for Once-Daily Dosing Frequency of Orfadin (nitisinone) for the Treatment of HT-1 57
05/17/2017: Orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1 58
04/17/2018: Sobi Receives Approval from Health Canada for Once-Daily Dosing of Orfadin (nitisinone) for the Treatment of HT-1 59
03/07/2017: FDA approves in-use storage at room temperature for Orfadin capsules 60
02/27/2018: Sobis Orfadin (nitisinone) Receives Positive Reimbursement Recommendation for the Treatment of HT-1 from CADTH Canadian Drug Expert Committee 61
02/02/2017: Sobi obtains approval from the European Commission for new dosing frequency of Orfadin 62
01/04/2017: Health Canada Approves Orfadin Capsules for Treatment of Hereditary Tyrosinaemia Type-1 (HT-1) 63
Product Approvals 64
Jan 23, 2018: FDA accepts investigational new drug application and grants Fast Track status for SOBI003 for the treatment of MPS IIIA 64
Jul 05, 2017: FDA grants SOBI003 Orphan Drug Designation for the treatment of MPS IIIA 65
Other Significant Developments 66
Apr 17, 2018: Sobi publishes 2017 Annual and Sustainability Report 66
Feb 28, 2018: Sobi Launches Enhanced Corporate Sustainability Initiative 67
Jun 05, 2017: Sobi Keeps the Partner Products Business Area as an Integral Part of the Company 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70

List Of Tables

List of Tables
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Swedish Orphan Biovitrum AB, Deals By Therapy Area, 2012 to YTD 2018 9
Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Swedish Orphan Biovitrum Plans to Sell Partner Products Business 14
Baylor Research Enters into Licensing Agreement with Swedish Orphan Biovitrum 15
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 16
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 17
ModiQuest Research Enters into Agreement with Swedish Orphan Biovitrum 18
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 19
Biogens Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 20
Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 21
Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 22
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 23
Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 24
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 25
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 27
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 29
Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 30
Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 31
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 32
Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 33
Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 34
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Only for Children Pharma For Neonatology Treatment 35
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 36
Swedish Orphan Biovitrum Announces Private Placement Of Senior Bonds Due 2017 For US$86 Million 38
Swedish Orphan Biovitrum AB, Key Competitors 39
Swedish Orphan Biovitrum AB, Key Employees 40
Swedish Orphan Biovitrum AB, Subsidiaries 41

List Of Figures

List of Figures
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11

Swedish Orphan Biovitrum AB (SOBI) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Swedish Orphan Biovitrum AB (Sobi), formerly Biovitrum AB, is an integrated biopharmaceutical company that focuses on the development of products for the treatment of rare diseases. The company specializes in

USD 250 View Report

Swedish Orphan Biovitrum AB Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Swedish Orphan Biovitrum AB Company Profile is a detailed strategic and analytical report on Swedish Orphan Biovitrum AB. The 2018 version of the report offers detailed insights into the companys

USD 200 View Report

Swedish Orphan Biovitrum AB Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Swedish Orphan Biovitrum AB Company Profile is a detailed strategic and analytical report on Swedish Orphan Biovitrum AB. The 2018 version of the report offers detailed insights into the companys

USD 200 View Report

Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review

Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled

USD 125 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available